Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein
Corresponding Author
Andrew C.R. Martin
School of Animal and Microbial Sciences, University of Reading, Reading, UK
School of Animal and Microbial Sciences, University of Reading, Whiteknights, PO Box 228, Reading RG6 6AJ, UKSearch for more papers by this authorAngelo M. Facchiano
CRISCEB-Research Center of Computational and Biotechnological Sciences, Second University of Naples, Naples, Italy
Search for more papers by this authorAlison L. Cuff
School of Animal and Microbial Sciences, University of Reading, Reading, UK
Search for more papers by this authorTina Hernandez-Boussard
International Agency for Research on Cancer, Lyon, France
Search for more papers by this authorMagali Olivier
International Agency for Research on Cancer, Lyon, France
Search for more papers by this authorPierre Hainaut
International Agency for Research on Cancer, Lyon, France
Search for more papers by this authorJanet M. Thornton
Biomolecular Structure and Modelling Unit, Department of Biochemistry and Molecular Biology, University College London, London, UK
Department of Crystallography, Birkbeck College, London, UK
Search for more papers by this authorCorresponding Author
Andrew C.R. Martin
School of Animal and Microbial Sciences, University of Reading, Reading, UK
School of Animal and Microbial Sciences, University of Reading, Whiteknights, PO Box 228, Reading RG6 6AJ, UKSearch for more papers by this authorAngelo M. Facchiano
CRISCEB-Research Center of Computational and Biotechnological Sciences, Second University of Naples, Naples, Italy
Search for more papers by this authorAlison L. Cuff
School of Animal and Microbial Sciences, University of Reading, Reading, UK
Search for more papers by this authorTina Hernandez-Boussard
International Agency for Research on Cancer, Lyon, France
Search for more papers by this authorMagali Olivier
International Agency for Research on Cancer, Lyon, France
Search for more papers by this authorPierre Hainaut
International Agency for Research on Cancer, Lyon, France
Search for more papers by this authorJanet M. Thornton
Biomolecular Structure and Modelling Unit, Department of Biochemistry and Molecular Biology, University College London, London, UK
Department of Crystallography, Birkbeck College, London, UK
Search for more papers by this authorAbstract
TP53 encodes p53, which is a nuclear phosphoprotein with cancer-inhibiting properties. In response to DNA damage, p53 is activated and mediates a set of antiproliferative responses including cell-cycle arrest and apoptosis. Mutations in the TP53 gene are associated with more than 50% of human cancers, and 90% of these affect p53-DNA interactions, resulting in a partial or complete loss of transactivation functions. These mutations affect the structural integrity and/or p53-DNA interactions, leading to the partial or complete loss of the protein’s function. We report here the results of a systematic automated analysis of the effects of p53 mutations on the structure of the core domain of the protein. We found that 304 of the 882 (34.4%) distinct mutations reported in the core domain can be explained in structural terms by their predicted effects on protein folding or on protein-DNA contacts. The proportion of “explained” mutations increased to 55.6% when substitutions of evolutionary conserved amino acids were included. The automated method of structural analysis developed here may be applied to other frequently mutated gene mutations such as dystrophin, BRCA1, and G6PD. Hum Mutat 19:149–164, 2002. © 2002 Wiley-Liss, Inc.
REFERENCES
- Aas T, Børresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug J, Akslen LA, Lonning P. 1996. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811–814.
- Ara S, Lee P, Hansen M, Saya H. 1990. Codon-72 polymorphism of the Tp53 gene. Nucleic Acids Res 18: 4961.
- Baker EN, Hubbard RE. 1984. Hydrogen bonding in globular proteins. Progr Biophy Mol Biol 44: 97–179.
- Brachmann RK, Eby KYY, Pavletich NP, Boeke JD. 1998. Genetic selection of intragenic suppressor mutations that reverse the effects of common p53 cancer mutations. EMBO J 17: 1847–1859.
- Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J. 1991. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88: 10124–10128.
- Chao C, Saito S, Kang J, Anderson C, Appella E, Xu Y. 2000. p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J 19: 4967–4975.
- Chiba I, Takahashi T, Nau MM, D’Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, Reissman P, Slamon DJ, Holmes EC, Minna JD. 1990. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5: 1603–1610.
- Cho Y, Gorina S, Jeffrey PD, Pavletich NP. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346–355.
- Clore GM, Ernst J, Clubb R, Omichinski JG, Kennedy WM, Sakaguchi K, Appella E, Gronenborn AM. 1995. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat Struct Biol 2: 321–333.
- Crawford L. 1983. The 53,000-dalton cellular protein and its role in transformation. Int Rev Exp Pathol 25: 1–50.
- Culotta E, Koshland Jr DE. 1993. p53 sweeps through cancer research. Science 262: 1958–1959.
- Felley-Bosco E, Weston A, Cawley H, Bennett W, Harris C. 1993. Functional studies of a germ-line polymorphism at codon-47 within the p53 gene. Am J Hum Genet 53: 752–759.
- Gannon JV, Greaves R, Iggo R, Lane DP. 1990. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9: 1595–1602.
- Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen D, Lillehaug J, Akslen L, Børresen-Dale A. 2001. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61: 2505–2512.
- Gorina S, Pavletich NP. 1996. Structure of the p53 tumour suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274: 1001–1005.
- Greenblatt MS, Bennett WP, Hollstein M, Harris CC. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855–4878.
- Guinn BA, Padua RA. 1995. p53: a role in the initiation and progression of leukaemia? Cancer J 8: 195–200.
- Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M, Harris CC, Montesano R. 1998. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res 26: 205–213.
- Harris CC. 1993. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262: 1980–1981.
- Harris CC. 1996. p53 tumor suppressor gene: from the basic research laboratory to the clinic — an abridged historical perspective. Carcinogenesis 17: 1187–1198.
- Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P. 1999. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum Mutat 14: 1–8.
- Irwin MS, Kaelin WGJ. 2001. Role of the newer p53 family proteins in malignancy. Apoptosis 6: 17–29.
- Jeffrey PD, Gorina S, Pavletich NP. 1995. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1. 7Ångströms. Science 267: 1498–1502.
- Jones DT, Taylor WR, Thornton JM. 1994. A mutation data matrix for transmembrane proteins. FEBS Lett 339: 269–275.
- Jones S, Thornton JM. 1996. Principles of protein–protein interactions. Proc Natl Acad Sci USA 93: 13–20.
- Jones S, Thornton JM. 1997. Prediction of protein–protein interaction sites using patch analysis. J Mol Biol 272: 133–143.
- Kabsch W, Sander C. 1983. Dictionary of protein secondary structure. Biopolymers 22: 2577–2637.
- Ko L, Prives C. 1996. p53: puzzle and paradigm. Genes Dev 10: 1054–1072.
- Kraulis PJ. 1991. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Cryst 24: 946–950.
- Lakin N, Jackson S. 1999. Regulation of p53 in response to DNA damage. Oncogene 18: 7644–7655.
- Laskowski RA, MacArthur MW, Moss DS, Thornton JM. 1993. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 26: 283–291.
- Laskowski R, Thornton JM, Humblet C, Singh J. 1996. X-SITE: Use of empirically derived atomic packing preferences to identify favourable interaction regions in the binding sites of proteins. J Mol Biol 259: 175–201.
- Lee BK, Richards FM. 1971. The interpretation of protein structures: estimation of static accessibility. J Mol Biol 55: 379–400.
- Levine AJ. 1997. p53, the cellular gatekeeper for growth and differentiation. Cell 88: 323–331.
- Li FP, Garber JE, Friend SH, Strong LC, Patenaude AF, Juengst ET, Reilly PR, Correa P, Fraumeni Jr JF. 1992. Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. J Natl Cancer Instit 84: 1156–1160.
- Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH. 1990. Germ line p53 mutations in a familial syndrome of breast-cancer, sarcomas, and other neoplasms. Science 250: 1233–1238.
- Matlashewski G. 1999. p53 twenty years on, meeting review. Oncogene 18: 7618–7620.
- Maurici D, Monti P, Campomenosi P, North S, Frebourg T, Fronza G, Hainaut P. 2001. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene 20: 3533–3540.
- May P, May E. 1999. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 18: 7621–7636.
- McDonald IK, Thornton JM. 1994. Satisfying hydrogen-bonding potential in proteins. J Mol Biol 238: 777–793.
- Merritt EA, Bacon DJ. 1997. Raster3D: photorealistic molecular graphics. Meth Enzymol 277: 505–524.
- Michalovitz D, Halevy O, Oren M. 1991. p53 mutations — gains or losses. J Cell Biochem 45: 22–29.
- Mittl PR, Chene P, Grutter MG. 1998. Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template. Acta Crystallogr D 54: 86–89.
- Nikolova PV, Wong KB, DeDecker B, Henckel J, Fersht AR. 2000. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J 19: 370–378.
- North S, Hainaut P. 2000. P53 and cell-cycle: a finger in every pie. Pathol Biol 48: 255–270.
- Pavletich NP, Chambers KA, Pabo CO. 1993. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev 7: 2556–2564.
- Romano JW, Ehrhart JC, Duthu A, Kim CM, Appella E, May P. 1989. Identification and characterization of a p53 gene in a human osteosarcoma cell line. Oncogene 4: 1483–1488.
- Shenkin PS, Erman B, Mastrandrea LD. 1991. Information-theoretical entropy as a measure of sequence variability. Proteins: Struct Funct Genet 11: 297–313.
- Shih HL, Brady J, Karplus M. 1985. Structure of proteins with single-site mutations: a minimum perturbation approach. Proc Natl Acad Sci USA 82: 1697–1700.
- Sigal A, Rotter V. 2000. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60: 6788–6793.
- Snow ME, Amzel LM. 1986. Calculating three-dimensional changes in protein structure due to amino acid substitutions: the variable domain of immunoglobulins. Proteins: Struct Funct Genet 1: 276–279.
- Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. 1990. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature (London) 348: 747–749.
- Vogelstein B, Kinzler KW. 1992. p53 and dysfunction. Cell 70: 523–526.
- Vogelstein B, Kinzler KW. 1994. X-rays strike p53 again. Nature (London) 370: 174–175.
- Vogelstein B, Lane D, Levine A. 2000. Surfing the p53 network. Nature (London) 408: 307–310.
- Walker D, Bond J, Tarone R, Harris C, Makalowski W, Boguski M, Greenblatt M. 1999. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene 18: 211–218.
- Wiederschain D, Gu J, Yuan ZM. 2001. Evidence for a distinct inhibitory factor in the regulation of p53 functional activity. J Biol Chem 276: 27999–28005.
- Wong KB, DeDecker BS, Freund SM, Proctor MR, Bycroft M, Fersht AR. 1999. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc Natl Acad Sci USA 96: 8438–8442.